Amit Paliwal, MD
Family Medicine · Pomona, CANPI 1790881159
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,611 of the $5,921 with a category attached, or 61.0%. 30 manufacturers reported payments, led by Pfizer at 30.9% of the total. Reporting peaked in 2024 at $2,421 and has fallen 80.4% since, to $474 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Modernatx, Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$360
- Novartis$320
- AstraZeneca$232
- Boston Scientific$213
- plus $2K from 24 others
Across 1,202 payments — averaging $4612.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.5M
- Pfizer$1.3M
- Janssen Research & Development, LLC$559K
- AbbVie$79K
- F. Hoffmann-la Roche AG$24K
- Mylan Inc.$19K
- plus $46K from 4 others
What the payments were for
- Travel & lodging$2,31039%
- Food & beverage$3,61161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $1,830 |
| Modernatx, Inc. | 8 | $1,431 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $360 |
| Novartis | 14 | $320 |
| AstraZeneca | 7 | $232 |
| Boston Scientific | 8 | $213 |
| Johnson & Johnson | 10 | $200 |
| Amgen | 8 | $163 |
| Exact Sciences | 2 | $141 |
| Novo Nordisk | 6 | $123 |
| SK Life Science, Inc. | 2 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Merck | 5 | $105 |
| GSK | 4 | $88 |
| Dexcom, Inc. | 2 | $59 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $59 |
| Boehringer Ingelheim | 2 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Medtronic(2 entities) | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $30 |
| Abbott | 1 | $25 |
| Venclose Inc. | 2 | $25 |
| Nevro Corp. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,921 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $85,847 |
| FarxigaDapagliflozin Propanediol | 42 | $47,685 |
| JanuviaSitagliptin Phosphate | 52 | $47,671 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $33,704 |
| OzempicSemaglutide | 23 | $24,771 |
| MounjaroTirzepatide | 19 | $20,265 |
| EntrestoSacubitril/Valsartan | 19 | $19,379 |
| JardianceEmpagliflozin | 18 | $18,813 |
| XareltoRivaroxaban | 25 | $17,069 |
| VascepaIcosapent Ethyl | 18 | $16,506 |
| TradjentaLinagliptin | 16 | $12,810 |
| Diclofenac Sodium | 93 | $11,015 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $8,969 |
| Omega-3 Acid Ethyl Esters | 68 | $8,269 |
| BrilintaTicagrelor | 12 | $7,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,830 | $85,84786 claims |
| AstraZenecaFarxiga, Brilinta | $232 | $55,67454 claims |
| MerckJanuvia | $105 | $47,67152 claims |
| GSKTrelegy Ellipta | $88 | $33,70428 claims |
| Boehringer IngelheimJardiance, Tradjenta | $51 | $31,62334 claims |
| Novo NordiskOzempic | $123 | $24,77123 claims |
| NovartisEntresto | $320 | $19,37919 claims |
| Johnson & JohnsonXarelto | $200 | $17,06925 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $37 | $4,19612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Pomona
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.